This webinar will provide a short introduction to immuno-oncology, the shortcomings of current standard of care, checkpoint inhibitors and the mechanism of action of oncolytic virotherapies. The featured speaker will discuss selective replication of the oncolytic virus VSV-GP in tumor cells, tumor cell lysis and reshaping of the tumor microenvironment. The results from this study will explore the potential of VSV-GP as an immuno-oncology enabler for a broad range of cancers in poorly “T-cell inflamed” tumors and highlight VSV-GP as a non-mutagenic virus that synergizes with other immunotherapies as well as targeted therapies.
Philipp Müller, PhD, Senior Principal Scientist, Cancer Immunology & Immune Modulation Department, Boehringer Ingelheim
Dr. Philipp Müller received his PhD in Biochemistry from the University of Basel in 2009 (Biozentrum, Prof. Jean Pieters), with a major focus on the immunology of infectious diseases, immune cell signalling and in vivo models of immune cell function as well as development. Over the last 10 years, his research has been dedicated to cancer immunology and immunotherapy. He has worked on and published in high ranking journals on the immune-promoting properties of antibody-drug-conjugates, bispecific antibody formats as well as agonistic antibodies, such as anti-CD40, and their therapeutic combination with immune-checkpoint blockade. Dr. Philipp Müller is currently leading a research/project team as a senior principal scientist within the cancer immunology & immune modulation department of Boehringer Ingelheim (Biberach an der Riß, Germany) with a major focus on next-generation oncolytic viruses and novel immuno-oncology concepts.Message Presenter
Who Should Attend?
This webinar will appeal to individuals with the following or related job titles:
- Research Scientists
- Clinical Researchers
- Medical Researchers
- Industry Scientists
- Lab Directors/PI
- Post Doc Students
- Grad Students
Working in the following research areas:
- Immune checkpoints
- Cancer immunology
- Biomarker discovery
- Companion diagnostics
- Molecular pathology
- Precision medicine
What You Will Learn
Attendees will learn about:
- Introduction to immuno-oncology
- Shortcomings of current standard of care
- Checkpoint inhibitors
- Mechanism of action of oncolytic virotherapy, e.g. VSV-GP
- Application of VSV-GP in different cancers
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company’s technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.
NanoString’s products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under the direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early-stage breast cancer.
Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable.
Leading researchers and institutions are finding that NanoString’s nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.
In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company’s goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.